FH and hereditary leiomyomatosis and renal cell cancer: Still, the combination of erlotinib and bevacizumab has shown moderate side effects and long-lasting partial responses, considered by others the standard of care for HLRCC / pRCC patients with the FH-mutated nuance13,16–19.